Macrophage migration inhibitory factor blockade reprograms macrophages and disrupts prosurvival signaling in acute myeloid leukemia.
Journal
Cell death discovery
ISSN: 2058-7716
Titre abrégé: Cell Death Discov
Pays: United States
ID NLM: 101665035
Informations de publication
Date de publication:
28 Mar 2024
28 Mar 2024
Historique:
received:
29
09
2023
accepted:
19
03
2024
revised:
14
03
2024
medline:
29
3
2024
pubmed:
29
3
2024
entrez:
29
3
2024
Statut:
epublish
Résumé
The malignant microenvironment plays a major role in the development of resistance to therapies and the occurrence of relapses in acute myeloid leukemia (AML). We previously showed that interactions of AML blasts with bone marrow macrophages (MΦ) shift their polarization towards a protumoral (M2-like) phenotype, promoting drug resistance; we demonstrated that inhibiting the colony-stimulating factor-1 receptor (CSF1R) repolarizes MΦ towards an antitumoral (M1-like) phenotype and that other factors may be involved. We investigated here macrophage migration inhibitory factor (MIF) as a target in AML blast survival and protumoral interactions with MΦ. We show that pharmacologically inhibiting MIF secreted by AML blasts results in their apoptosis. However, this effect is abrogated when blasts are co-cultured in close contact with M2-like MΦ. We next demonstrate that pharmacological inhibition of MIF secreted by MΦ, in the presence of granulocyte macrophage-colony stimulating factor (GM-CSF), efficiently reprograms MΦ to an M1-like phenotype that triggers apoptosis of interacting blasts. Furthermore, contact with reprogrammed MΦ relieves blast resistance to venetoclax and midostaurin acquired in contact with CD163
Identifiants
pubmed: 38548753
doi: 10.1038/s41420-024-01924-5
pii: 10.1038/s41420-024-01924-5
doi:
Types de publication
Journal Article
Langues
eng
Pagination
157Informations de copyright
© 2024. The Author(s).
Références
Burnett AK, Hills RK, Russell N. Twenty five years of UK trials in acute myeloid leukaemia: what have we learned? Br J Haematol. 2020;188:86–100.
pubmed: 31828788
doi: 10.1111/bjh.16359
Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77.
pubmed: 35797463
doi: 10.1182/blood.2022016867
Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, et al. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020;11:5327.
pubmed: 33087716
pmcid: 7577981
doi: 10.1038/s41467-020-19119-8
Gurnari C, Pagliuca S, Visconte V. Deciphering the therapeutic resistance in acute myeloid leukemia. Int J Mol Sci. 2020;21:8505.
pubmed: 33198085
pmcid: 7697160
doi: 10.3390/ijms21228505
Davidson-Moncada J, Viboch E, Church SE, Warren SE, Rutella S. Dissecting the immune landscape of acute myeloid leukemia. Biomedicines. 2018;6:110.
pubmed: 30477280
pmcid: 6316310
doi: 10.3390/biomedicines6040110
Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003;3:791–800.
pubmed: 14502271
pmcid: 7097468
doi: 10.1038/nri1200
Abdul-Aziz AM, Shafat MS, Mehta TK, Di Palma F, Lawes MJ, Rushworth SA, et al. MIF-induced stromal PKCbeta/IL8 is essential in human acute myeloid leukemia. Cancer Res. 2017;77:303–11.
pubmed: 27872094
doi: 10.1158/0008-5472.CAN-16-1095
Islam M, Mohamed EH, Esa E, Kamaluddin NR, Zain SM, Yusoff YM, et al. Circulating cytokines and small molecules follow distinct expression patterns in acute myeloid leukaemia. Br J Cancer. 2017;117:1551–6.
pubmed: 28898234
pmcid: 5680464
doi: 10.1038/bjc.2017.316
Ding H, Feng Y, Xu J, Lin Z, Huang J, Wang F, et al. A novel immune prognostic model of non-M3 acute myeloid leukemia. Am J Transl Res. 2022;14:5308–25.
pubmed: 36105048
pmcid: 9452334
Jankauskas SS, Wong DWL, Bucala R, Djudjaj S, Boor P. Evolving complexity of MIF signaling. Cell Signal. 2019;57:76–88.
pubmed: 30682543
doi: 10.1016/j.cellsig.2019.01.006
Gordin M, Tesio M, Cohen S, Gore Y, Lantner F, Leng L, et al. c-Met and its ligand hepatocyte growth factor/scatter factor regulate mature B cell survival in a pathway induced by CD74. J Immunol. 2010;185:2020–31.
pubmed: 20639480
doi: 10.4049/jimmunol.0902566
Zheng Y, Yang J, Qian J, Qiu P, Hanabuchi S, Lu Y, et al. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia. 2013;27:702–10.
pubmed: 22996336
doi: 10.1038/leu.2012.272
Reinart N, Nguyen PH, Boucas J, Rosen N, Kvasnicka HM, Heukamp L, et al. Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor. Blood. 2013;121:812–21.
pubmed: 23118218
doi: 10.1182/blood-2012-05-431452
White ES, Strom SR, Wys NL, Arenberg DA. Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity. J Immunol. 2001;166:7549–55.
pubmed: 11390510
doi: 10.4049/jimmunol.166.12.7549
Noe JT, Mitchell RA. MIF-dependent control of tumor immunity. Front Immunol. 2020;11:609948.
pubmed: 33324425
pmcid: 7724107
doi: 10.3389/fimmu.2020.609948
Calandra T, Bernhagen J, Mitchell RA, Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med. 1994;179:1895–902.
pubmed: 8195715
doi: 10.1084/jem.179.6.1895
Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018;17:887–904.
pubmed: 30361552
doi: 10.1038/nrd.2018.169
Gutierrez-Gonzalez A, Martinez-Moreno M, Samaniego R, Arellano-Sanchez N, Salinas-Munoz L, Relloso M, et al. Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma. Blood. 2016;128:2241–52.
pubmed: 27625360
doi: 10.1182/blood-2016-01-695395
Edwards DKT, Watanabe-Smith K, Rofelty A, Damnernsawad A, Laderas T, Lamble A, et al. CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells. Blood. 2019;133:588–99.
pubmed: 30425048
pmcid: 6367650
doi: 10.1182/blood-2018-03-838946
Cencini E, Fabbri A, Sicuranza A, Gozzetti A, Bocchia M. The role of tumor-associated macrophages in hematologic malignancies. Cancers. 2021;13:3597.
pubmed: 34298810
pmcid: 8304632
doi: 10.3390/cancers13143597
Smirnova T, Spertini C, Spertini O. CSF1R inhibition combined with GM-CSF reprograms macrophages and disrupts protumoral interplays with AML cells. Cancers. 2021;13:5289.
pubmed: 34771453
pmcid: 8582394
doi: 10.3390/cancers13215289
Wang Q, Lu Y, Li R, Jiang Y, Zheng Y, Qian J, et al. Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma. Leukemia. 2017;32:176–83.
pubmed: 28626216
pmcid: 5927777
doi: 10.1038/leu.2017.193
Quail DF, Joyce JA. Molecular pathways: deciphering mechanisms of resistance to macrophage-targeted therapies. Clin Cancer Res. 2017;23:876–84.
pubmed: 27895033
doi: 10.1158/1078-0432.CCR-16-0133
Winner M, Meier J, Zierow S, Rendon BE, Crichlow GV, Riggs R, et al. A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells. Cancer Res. 2008;68:7253–7.
pubmed: 18794110
pmcid: 2726006
doi: 10.1158/0008-5472.CAN-07-6227
Yaddanapudi K, Putty K, Rendon BE, Lamont GJ, Faughn JD, Satoskar A, et al. Control of tumor-associated macrophage alternative activation by macrophage migration inhibitory factor. J Immunol. 2013;190:2984–93.
pubmed: 23390297
doi: 10.4049/jimmunol.1201650
Barbosa de Souza Rizzo M, Brasilino de Carvalho M, Kim EJ, Rendon BE, Noe JT, Darlene Wise A, et al. Oral squamous carcinoma cells promote macrophage polarization in an MIF-dependent manner. QJM. 2018;111:769–78.
pubmed: 30016493
pmcid: 6217709
doi: 10.1093/qjmed/hcy163
Andrew L, Chun Shik P, Ye S, Nam Kyung L, Lacorazza HD. Chemical inhibition of the macrophage inhibitor factor (MIF) induces cell cycle arrest and apoptosis in lymphoid and myeloid leukemia. Blood. 2017;130:1329.
Georgouli M, Papadimitriou L, Glymenaki M, Patsaki V, Athanassakis I. Expression of MIF and CD74 in leukemic cell lines: correlation to DR expression destiny. Biol Chem. 2016;397:519–28.
pubmed: 26866879
doi: 10.1515/hsz-2015-0280
Fertal SA, Zaidi SK, Stein JL, Stein GS, Heath JL. CXCR4 mediates enhanced cell migration in CALM-AF10 leukemia. Front Oncol. 2021;11:708915.
pubmed: 35070954
doi: 10.3389/fonc.2021.708915
Liang J, Wang S, Zhang G, He B, Bie Q, Zhang B. A new antitumor direction: tumor-specific endothelial cells. Front Oncol. 2021;11:756334.
pubmed: 34988011
pmcid: 8721012
doi: 10.3389/fonc.2021.756334
Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 2008;13:453–61.
pubmed: 17981560
doi: 10.2741/2692
DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7–17.
pubmed: 30361262
pmcid: 6318429
doi: 10.1182/blood-2018-08-868752
Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299–312.
pubmed: 30651634
pmcid: 6365380
doi: 10.1038/s41375-018-0357-9
Li D, Li H, Cheng C, Li G, Yuan F, Mi R, et al. All-trans retinoic acid enhanced the antileukemic efficacy of ABT-199 in acute myeloid leukemia by downregulating the expression of S100A8. Int Immunopharmacol. 2022;112:109182.
pubmed: 36058034
doi: 10.1016/j.intimp.2022.109182
Kühnl A, Kaiser M, Neumann M, Fransecky L, Heesch S, Radmacher M, et al. High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia. Leuk Res. 2011;35:1585–90.
pubmed: 21899885
pmcid: 4023812
doi: 10.1016/j.leukres.2011.08.006
Jacamo R, Chen Y, Wang Z, Ma W, Zhang M, Spaeth EL, et al. Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance. Blood. 2014;123:2691–702.
pubmed: 24599548
pmcid: 3999754
doi: 10.1182/blood-2013-06-511527
Peña-Martínez P, Eriksson M, Ramakrishnan R, Chapellier M, Högberg C, Orsmark-Pietras C, et al. Interleukin 4 induces apoptosis of acute myeloid leukemia cells in a Stat6-dependent manner. Leukemia. 2018;32:588–96.
pubmed: 28819278
doi: 10.1038/leu.2017.261
Smirnova T, Bonapace L, MacDonald G, Kondo S, Wyckoff J, Ebersbach H, et al. Serpin E2 promotes breast cancer metastasis by remodeling the tumor matrix and polarizing tumor associated macrophages. Oncotarget. 2016;7:82289–304.
pubmed: 27793045
pmcid: 5347692
doi: 10.18632/oncotarget.12927
Benechet AP, Menon M, Xu D, Samji T, Maher L, Murooka TT, et al. T cell-intrinsic S1PR1 regulates endogenous effector T-cell egress dynamics from lymph nodes during infection. Proc Natl Acad Sci USA. 2016;113:2182–7.
pubmed: 26862175
pmcid: 4776484
doi: 10.1073/pnas.1516485113
Yang LX, Zhang CT, Yang MY, Zhang XH, Liu HC, Luo CH, et al. C1Q labels a highly aggressive macrophage-like leukemia population indicating extramedullary infiltration and relapse. Blood. 2023;141:766–86.
pubmed: 36322939
doi: 10.1182/blood.2022017046
Zhou J, Chen X, Zhou P, Sun X, Chen Y, Li M, et al. Osteopontin is required for the maintenance of leukemia stem cells in acute myeloid leukemia. Biochem Biophys Res Commun. 2022;600:29–34.
pubmed: 35182972
doi: 10.1016/j.bbrc.2022.02.022
Que Y, Li H, Lin L, Zhu X, Xiao M, Wang Y, et al. Study on the immune escape mechanism of acute myeloid leukemia with DNMT3A mutation. Front Immunol. 2021;12:653030.
pubmed: 34093541
pmcid: 8173207
doi: 10.3389/fimmu.2021.653030
Shi X, Leng L, Wang T, Wang W, Du X, Li J, et al. CD44 is the signaling component of the macrophage migration inhibitory factor–CD74 receptor complex. Immunity. 2006;25:595–606.
pubmed: 17045821
pmcid: 3707630
doi: 10.1016/j.immuni.2006.08.020
Cao H, Tadros V, Hiramoto B, Leeper K, Hino C, Xiao J, et al. Targeting TKI-activated NFKB2-MIF/CXCLs-CXCR2 signaling pathways in FLT3 mutated acute myeloid leukemia reduced blast viability. Biomedicines. 2022;10:1038.
pubmed: 35625776
pmcid: 9138861
doi: 10.3390/biomedicines10051038
de Azevedo RA, Shoshan E, Whang S, Markel G, Jaiswal AR, Liu A, et al. MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma. Oncoimmunology. 2020;9:1846915.
pubmed: 33344042
pmcid: 7733907
doi: 10.1080/2162402X.2020.1846915
Figueiredo CR, Azevedo RA, Mousdell S, Resende-Lara PT, Ireland L, Santos A, et al. Blockade of MIF-CD74 signalling on macrophages and dendritic cells restores the antitumour immune response against metastatic melanoma. Front Immunol. 2018;9:1132.
pubmed: 29875777
pmcid: 5974174
doi: 10.3389/fimmu.2018.01132
Yaddanapudi K, Rendon BE, Lamont G, Kim EJ, Al Rayyan N, Richie J, et al. MIF is necessary for late-stage melanoma patient MDSC immune suppression and differentiation. Cancer Immunol Res. 2016;4:101–12.
pubmed: 26603621
doi: 10.1158/2326-6066.CIR-15-0070-T
Simpson KD, Templeton DJ, Cross JV. Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloid-derived suppressor cells in the tumor microenvironment. J Immunol. 2012;189:5533–40.
pubmed: 23125418
doi: 10.4049/jimmunol.1201161
Mitchell RA. Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell Signal. 2004;16:13–9.
pubmed: 14607271
doi: 10.1016/j.cellsig.2003.07.002
Chesney JA, Mitchell RA. 25 Years on: a retrospective on migration inhibitory factor in tumor angiogenesis. Mol Med. 2015;21:S19–24.
pubmed: 26605643
pmcid: 4661055
doi: 10.2119/molmed.2015.00055
Zheng L, Feng Z, Tao S, Gao J, Lin Y, Wei X, et al. Destabilization of macrophage migration inhibitory factor by 4-IPP reduces NF-κB/P-TEFb complex-mediated c-Myb transcription to suppress osteosarcoma tumourigenesis. Clin Transl Med. 2022;12:e652.
pubmed: 35060345
pmcid: 8777168
doi: 10.1002/ctm2.652
Cournia Z, Leng L, Gandavadi S, Du X, Bucala R, Jorgensen WL. Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. J Med Chem. 2009;52:416–24.
pubmed: 19090668
pmcid: 2680181
doi: 10.1021/jm801100v
Merk M, Baugh J, Zierow S, Leng L, Pal U, Lee SJ, et al. The Golgi-associated protein p115 mediates the secretion of macrophage migration inhibitory factor. J Immunol. 2009;182:6896–906.
pubmed: 19454686
doi: 10.4049/jimmunol.0803710
Garcia-Gerique L, García M, Garrido-Garcia A, Gómez-González S, Torrebadell M, Prada E, et al. MIF/CXCR4 signaling axis contributes to survival, invasion, and drug resistance of metastatic neuroblastoma cells in the bone marrow microenvironment. BMC Cancer. 2022;22:669.
pubmed: 35715791
pmcid: 9206243
doi: 10.1186/s12885-022-09725-8
Schmetzer HM, Gerhartz HH, Wilmanns W. GM-CSF stimulates proliferation of clonal leukemic bone marrow cells in acute myeloid leukemia (AML) in vitro. Ann Hematol. 1999;78:449–55.
pubmed: 10550555
doi: 10.1007/s002770050597
Kumar A, Taghi Khani A, Sanchez Ortiz A, Swaminathan S. GM-CSF: a double-edged sword in cancer immunotherapy. Front Immunol. 2022;13:901277.
pubmed: 35865534
pmcid: 9294178
doi: 10.3389/fimmu.2022.901277
Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.
pubmed: 27895058
pmcid: 5291965
doi: 10.1182/blood-2016-08-733196
Petrov JC, Wada M, Pinz KG, Yan LE, Chen KH, Shuai X, et al. Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia. Leukemia. 2018;32:1317–26.
pubmed: 29515236
pmcid: 5990523
doi: 10.1038/s41375-018-0075-3
Smirnova T, Zhou ZN, Flinn RJ, Wyckoff J, Boimel PJ, Pozzuto M, et al. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis. Oncogene. 2012;31:706–15.
pubmed: 21725367
doi: 10.1038/onc.2011.275
Bénéchet AP, De Simone G, Di Lucia P, Cilenti F, Barbiera G, Le Bert N, et al. Dynamics and genomic landscape of CD8(+) T cells undergoing hepatic priming. Nature. 2019;574:200–5.
pubmed: 31582858
pmcid: 6858885
doi: 10.1038/s41586-019-1620-6